Citi analyst Yigal Nochomovitz lowered the firm’s price target on Apellis Pharmaceuticals to $67 from $70 and keeps a Buy rating on the shares. The analyst reduced the probability of sucess for Syfovre in Europe from 75% to 50% on the news that the Committee for Medicinal Products for Human Use does not appear convinced the effects on geographic atrophy lesion growth are translating to a meaningful functional benefit, resulting in a negative trend vote.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLS:
- Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
- Apellis expects CHMP to adopt negative opinion on MAA for pegcetacoplan
- Apellis says EMPAVELI provided long-term control of PNH
- EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
